MedTrace Logo

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

NCT05859464 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-10-17

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with advanced solid tumor malignancies.

Conditions

  • Malignant Solid Tumor

Interventions

DRUG

ZL-1218

ZL-1218 dose escalation

DRUG

Pembrolizumab

Combination treatment with ZL-1218

Sponsors & Collaborators

  • Zai Biopharmaceutical (Shanghai) Co., Ltd.

    collaborator UNKNOWN

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Zai Lab (Hong Kong), Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-24
Primary Completion
2025-08-28
Completion
2025-08-28
FDA Drug
Yes

Countries

  • United States
  • China
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05859464 on ClinicalTrials.gov